PRESSING病例对照研究:转移性结直肠癌抗EGFR单抗的超选择负向预测
该多中心前瞻性病例对照研究纳入RAS和BRAF野生型转移性结直肠癌患者,每组47例,评估包含HER2/MET扩增、ALK/ROS1/NTRK1-3/RET融合及PIK3CA突变的PRESSING panel对anti-EGFR单抗原发耐药的负向预测价值。结果显示该panel改变在耐药组显著多于敏感组(51.1% vs 2.1%,P<0.001),联合肿瘤侧别预测准确性达80.4%。
要点
- PRESSING panel改变在耐药组占51.1%,敏感组仅2.1%,差异显著(P<0.001)。
- 右侧肿瘤panel改变频率高于左侧(41.4% vs 20.0%,P=0.03)。
- panel联合侧别预测准确性80.4%,高于panel单独75.3%和侧别单独70.2%。
核心结论
- 所研究的基因组改变panel有助于细化RAS和BRAF野生型mCRC患者中anti-EGFR单抗候选者的选择,部分解释并进一步佐证原发肿瘤侧别的预测能力。
研究设计与样本
- 多中心、前瞻性、病例对照研究,耐药组和敏感组各纳入47例RAS和BRAF野生型转移性结直肠癌患者。
主要发现
- PRESSING panel改变在耐药组24/47(51.1%)vs 敏感组1/47(2.1%),P<0.001。
- 右侧肿瘤panel改变12/29(41.4%)vs 左侧肿瘤13/65(20.0%),P=0.03。
- PRESSING panel和肿瘤侧别的预测准确性分别为75.3%和70.2%;联合评估为80.4%。
- 在超选择患者中,右侧仍与耐药相关(P=0.002)。
- 二次分析中,耐药组8例(17.0%)vs 敏感组0例存在微卫星不稳定(P<0.001)。
关键数值与推荐
- PRESSING panel包括HER2/MET扩增、ALK/ROS1/NTRK1-3/RET融合和PIK3CA突变。
- 假设耐药组和敏感组候选改变患病率分别为15%和0%,双侧α=0.05、β=0.20,每组需47例。
临床怎么用
- 在RAS和BRAF野生型mCRC患者中,检测PRESSING panel联合原发肿瘤侧别可能有助于细化anti-EGFR单抗的候选选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Refining the selection of metastatic colorectal cancer patients candidates for anti-epidermal growth factor receptor (EGFR) monoclonal antibodies beyond RAS and BRAF testing is a challenge of precision oncology. Several uncommon genomic mechanisms of primary resistance, leading to activation of tyrosine kinase receptors other than EGFR or downstream signalling pathways, have been suggested by preclinical and retrospective studies. PATIENTS AND METHODS: We conducted this multicentre, prospective, case-control study to demonstrate the negative predictive impact of a panel of rare genomic alterations [PRESSING (PRimary rESiStance IN RAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-eGfr monoclonal antibodies) panel], including HER2/MET amplifications, ALK/ROS1/NTRK1-3/RET fusions and PIK3CA mutations. Hypothesizing a prevalence of candidate alterations of 15% and 0% in resistant and sensitive RAS and BRAF wild-type patients, respectively, with two-sided α and β errors of 0.05 and 0.20, 47 patients per group were needed. RESULTS: Forty-seven patients per group were included. PRESSING panel alterations were significantly more frequent in resistant (24 out of 47, 51.1%) than in sensitive (1 out of 47, 2.1%) patients (P < 0.001) and in right- (12 out of 29, 41.4%) than left-sided (13 out of 65, 20.0%) tumours (P = 0.03). The predictive accuracy of PRESSING panel and sidedness was 75.3% and 70.2%, respectively. Among hyper-selected patients, right-sidedness was still associated with resistance (P = 0.002). The predictive accuracy of the combined evaluation of PRESSING panel and sidedness was 80.4%. As a secondary analysis, 8 (17.0%) resistant and 0 sensitive patients showed microsatellite instability (P < 0.001). CONCLUSION: The investigated panel of genomic alterations allows refining the selection of RAS and BRAF wild-type metastatic colorectal cancer patients candidates for anti-EGFRs, partially explaining and further corroborating the predictive ability of primary tumour sidedness.
引用
- Cremolini C, Morano F, Moretto R, et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann Oncol. 2017. PMID: 29045518. doi:10.1093/annonc/mdx546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。